Lavoltidine

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLavoltidine
Drug Alias Name拉伏替丁loxtidineAH-23844AH-23844A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThromboxane A2 receptor antagonistsHistamine H2 receptor antagonists
TargetsThromboxane A2 receptorHistamine H2 receptor
Therapy Area/IndicationsGastroesophageal Reflux
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsGastroesophageal Reflux

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG